Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism.
Adoptive immunotherapy with cyclophosphamide (Cy) increases the host resistance against tumor growth. The precise mechanism(s) by which this therapy enhances tumor suppression is unclear. Cy induces the development of early myeloid cells that may be strongly antiproliferative through NO production. These cells are similar to the natural suppressor cells found in normal bone marrow with a potential antitumor effect. Here we have addressed whether the development of NO-producing cells may be involved in this tumor resistance in Cy-treated mice. The results show a synergism between Cy treatment and tumor-specific lymphocytes transferred systemically (i.v.) or locally (Winn's assay) that results in a strong tumor suppression. Inhibition of NO production by N(G)-monomethyl-L-arginine at the site of tumor inoculation results in a loss of the protection achieved by the combined therapy. Cy-treated mice develop splenic early myeloid (CD11b, Gr-1, CD31 (ER-MP12), ER-MP20, ER-MP54) cells producing large amounts of NO upon T cell-derived signals (IFN-gamma plus CD40 ligation) able to inhibit tumor cell growth in vitro. Early myeloid cells (ER-MP54(+)) and cells expressing inducible NO synthase are increased at the site of tumor challenge in mice treated with the combined therapy, but not in those treated with Cy or immune cell transfer alone. Thus, Cy induces the expansion of early myeloid cells, inhibiting tumor cell growth by a mechanism involving NO. Both the recruitment and the activation of these myeloid cells at the site of tumor challenge appear to be dependent on the presence of tumor-specific lymphocytes.
Peláez
B
B
Departments of Immunology and Pathology, Hospital Clínico San Carlos, Madrid, Spain.
Campillo
J A
JA
López-Asenjo
J A
JA
Subiza
J L
JL
D019264:Adoptive Transfer; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D002286:Carcinoma, Ehrlich Tumor / Q000276:immunology / Q000378:metabolism / Q000473:pathology* / Q000517:prevention & control*; D002454:Cell Differentiation / Q000187:drug effects / Q000276:immunology; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D006131:Growth Inhibitors / Q000008:administration & dosage / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D007274:Injections, Intraperitoneal; D008213:Lymphocyte Activation; D017710:Lymphocyte Transfusion; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D022423:Myeloid Cells / Q000166:cytology* / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D009569:Nitric Oxide / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D013154:Spleen / Q000166:cytology / Q000378:metabolism / Q000637:transplantation; D014407:Tumor Cells, Cultured / Q000637:transplantation
D018906:Antineoplastic Agents, Alkylating; D006131:Growth Inhibitors; D009569:Nitric Oxide; D003520:Cyclophosphamide